Oral, head and neck cancer research at Providence Cancer Center
October 21, 2016
Providence Oral, Head and Neck Cancer Clinic offers world-class care for patients with benign and malignant tumors of the oral cavity (mouth), tongue, pharynx (throat), larynx (voice box), nose, paranasal sinuses, salivary glands and thyroid gland, as well as tumors at the skull base. Our medical and surgical oncology teams work collaboratively to start patients on treatment regimens very quickly.
The clinic’s co-directors – medical oncologist Rom Leidner, M.D., and oncological surgeon R. Bryan Bell, M.D., D.D.S., FACS – are innovative leaders committed to elevating the current standard of care for oncology patients by offering advancements such as pre-operative immunotherapy. Their aim is to improve surgical outcomes and reduce the risk of recurrence.
Following are two of the 10 oral, head and neck cancer studies currently open to patients:
Title: Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered prior to Definitive Surgical Resection in Patients With Locoregionally Advanced Oral, Head and Neck Squamous Cell Carcinoma
Description: The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.
Title: Intratumoral Ipilimumab in Head and Neck Cancer*
Description: This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.
*This study will be posted soon – please watch our clinical trials website. New studies are posted daily.
Click here to see all oral, head and neck cancer studies currently open to patients.